3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
16
Uterine Cervical Neoplasms
5
Rectal Neoplasms
5
Pancreatic Neoplasms
5
Colonic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Prostatic Neoplasms
2
Neoplasms
2
Hemangiosarcoma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Resectable MMR-deficient Solid Tumors
1
Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Microsatellite Stable Rectal Carcinoma
1
Melanoma
1
Lymphoma
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Interventions
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Resectable MMR-deficient Solid Tumors
×
balstilimab
×
Clear all
NCT06279130
2026-03-05
NEOASIS
The Netherlands Cancer Institute
Phase 2/3
Recruiting
133 enrolled